The place of vericiguat in treatment of patients with heart failure and reduced ejection fraction following a worsening heart failure event

Author: Daniel Lovrić
Abstract:

In patients with heart failure, any worsening heart failure event, such as the need for intravenous diuretics, the emergency department examination or hospitalization, is an independent risk factor for future adverse events and premature cardiovascular death. In such high risk patients with lower average functional capacity compared to the patients in recent large heart failure trials, vericiguat showed significant reduction of composite endpoint of cardiovascular death or heart failure hospitalization with a safety profile comparable to placebo, with simple, once a day dosing with food, without the need for washout period.

Key words:
cardiovascular death; heart failure; heart failure hospitalization; vericiguat


OGLASI